pexels-rodnae-productions-6129502.jpg

Our Company

Management

The Company also has a non-compensated Medical Advisory Board. Some members of the Company’s Medical Advisory Board are shareholders in American Radiosurgery, Inc. The Medical Advisory Board is not expected to have day-to-day operational responsibilities for the Company. Additional biography information on the Medical Advisory Board members is provided herein.

 

John P. Clark

CEO

Mr. Clark brings over 35 years of medical sales and business experience and is the founder, Chairman and CEO of Global Cancer Technology, Inc. Mr. Clark specializes in the development and commercialization of medical technologies into going corporate concerns. Mr. Clark has purchased technologies and develop patents for various medical applications. Concurrently, Mr. Clark serves as a Board of Director and Chairman of the Board Finance Committee for Palomar Health, a $1.5 Billion asset California District Hospital System. Most recently Mr. Clark has founded and organized:

 

American Radiosurgery, Inc. The Company produced and sold the RGS Vertex360, a multi-million dollar radiosurgery device that competed with the Elekta Gamma Knife in treating brain tumors noninvasively with precise radiation. It was the first American Company to produce a competitive device to the Gamma Knife and systems were placed in the US and in International markets.

 

The Rotating Gamma Institute–Orange County and the Rotating Gamma Institute–San Diego. These companies are independent non-invasive brain tumor treatment centers that began as partnerships with neurosurgeons, radiation oncologists and other private investors.

Marc Potvin

President

Marc has 25 years in operations, sales & marketing, engineering, supply chain and strategy roles throughout the US and globally. He has spent the past 15 years’ experience in the medical device market space.

 

Marc is a seasoned entrepreneur who founded Agility Management in 2008, a Human Capital company sold in 2015. He has served as a Board member of Connect/SDSI, a leading business incubator for start-ups that is based in San Diego. Marc will serve as President of NanoMed Tracking, Inc, a subsidiary of Global Cancer Technology, Inc. Marc has been instrumental in the development of the medical instrument marking process within NanoMed Tracking, Inc.

Mr. Peter Hanson

Chief Financial Officer

Mr. Hanson has over 30 years of experience in the areas of finance and operations. He began his career in public accounting and became a partner with Arthur Young & Company, the predecessor of Ernst & Young.

 

As an audit partner, Mr. Hanson handled a wide variety of clients, both public and privately held. His responsibilities included being the head of the Emerging Business practice for the Boston Office of Arthur Young. After leaving Arthur Young, Mr. Hanson has experienced a wide variety of experiences including serving as Chief Financial Officer for NuCorp Energy and Mitchell International. He also was a principal of Polaris Capital, an investment-banking firm that specialized in leveraged buy-outs.

 

In addition to financial responsibilities, Mr. Hanson also has considerable operations experience as he also served as Executive Vice President of Operations for Mitchell International and more recently as President of the American Association of Franchisees and Dealer.

Milan Makale. PhD, MSEE

Chief Technical Officer

Dr. Makale has been a scientist at UCSD since 2001. He is a Research Scientist-Bioengineer in Neuro-Oncology at the Moores Cancer Center. Dr. Makale has a PhD in radiation biology and MSEE (electrical engineering and computer science) specializing in biomedical engineering with a focus on development of radiation sensitizers, cell cycle checkpoint inhibitors, theranostic nanoparticles, neurotechnology and neural devices.

Board of Directors

The Board of Directors of the Company is primarily responsible for and charged with overseeing all business and operations of the Company. The Board elects the president as well as all other officers of the Company who in turn are primarily responsible for the day-to-day business and operations of the Company.

 

John P. Clark

Mr. Clark has served as CEO of the Company since its inception in 2017 and served as manager of the Company’s predecessor, Global Cancer Technology LLC since 2013.  He has also served as CEO of NanoMed Tracking, Inc., the Company’s subsidiary, since its inception in 2017.  He has served as Chairman and CEO of American Radiosurgery, Inc. since 2001.  Mr. Clark received a Bachelor of Science degree in biology in 1974 from the University of Scranton, Pennsylvania.

Mr. Tom Silberg

Thomas H Silberg is a seasoned professional in the Pharmaceutical and Biopharmaceutical Industries with substantial executive level experience, including major branded pharmaceuticals, medium sized biotech, start-up biotech and generic IV drug manufacturing. He has led multiple strategic transactions from a company divestiture and a public company spin out to asset acquisitions and partnerships. His career began in 1972 with Hoffmann La Roche, Inc. where he started in sales and advanced to VP of Business Operations.

 

He is a graduate from the University of Minnesota, where he earned a BS degree in Advertising and Marketing His past Board appointments include the USC Center of Excellence in HealthCare Management, Medi Promotions, the Cobalis Corporation and the Generic Pharmaceutical Manufacturers Association. He is currently a member of the Board of Directors for Pivotal Biosciences, Cardiocell, LLC, and Stemcutis, LLC and serves as Chairman of the Board for Genway Biotech, Inc., and the Palomar Health System Foundation.

Mr. Peter Hanson

Mr. Hanson has over 30 years of experience in the areas of finance and operations. He began his career in public accounting and became a partner with Arthur Young & Company, the predecessor of Ernst & Young.  As an audit partner, Mr. Hanson handled a wide variety of clients, both public and privately held. His responsibilities included being the head of the Emerging Business practice for the Boston Office of Arthur Young. After leaving Arthur Young, Mr. Hanson has experienced a wide variety of experiences including serving as Chief Financial Officer for NuCorp Energy and Mitchell International.

 

He also was a principal of Polaris Capital, an investment-banking firm that specialized in leveraged buy-outs. In addition to financial responsibilities, Mr. Hanson also has considerable operations experience as he also served as Executive Vice President of Operations for Mitchell International and more recently as President of the American Association of Franchisees and Dealers.

Scientific & Medical Advisory Group

Central to Global Cancer Technology, Inc.’s strategic direction is the identification and development of proprietary products and platform technologies to better meet identified clinical demand. The Scientific Advisory Group plays a key role in meeting this objective. The charter for this Group is to work with the Global Cancer Technology, INC. and the Manufacturing Division to identify and advise on new proprietary devices and consider technologies with broad clinical applications.

 

Dr. Santosh Kesari

 

Dr. Santosh Kesari is a world-renowned board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute. He is also Director of Neuro-Oncology, Providence Saint John’s Health Center and Member, Los Angeles Biomedical Research Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal.

 

He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech start-ups.

 

Dr. Kesari graduated from University of Pennsylvania, School of Arts and Sciences in 1992 and earned a Ph.D. degree in molecular biology and a M.D. from the University of Pennsylvania, School of Medicine. He completed his residency in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School and his neuro-oncology fellowship at the Dana-Farber Cancer Institute in Boston.

 

He was previously assistant professor of neurology at Harvard Medical School/Dana-Farber Cancer Institute/Brigham and Women’s Hospital and then professor of neurosciences at UC San Diego.

Sadik Esener, PhD

 

Applied Physics and Electrical Engineering from UCSD Professor of Nanoengineering and Electrical and Computer Engineering at UC San Diego. Internationally known expert in photonics, opto-electronics, and cancer nanotechnology. Sadik served as director of major research centers including NCI funded NanoTumor Center at UCSD. Specializes in cancer nanotechnology, in vivo imaging, optical systems and their interface with electronics and software. Sadik has been closely involved with 12 startup companies as co-founder including Genoptix, Nanogen, OriMedix, Devacell, and Ziva. Authored more than 350 publications.

Wolf Wrasidlo, PhD

 

Organic Chemistry from San Diego State University & University of Erlangen. Highly experienced polymer and organic chemist. Head of the Chemical Biology Program at the Moore’s Cancer Center at the UC San Diego School of Medicine and a Research Scientist in the Department of Neuroscience. Held senior level positions at The Scripps Research Institute, Humboldt University Berlin Medical School, University of Tuebingen Childrens' Hospital, and Columbia University. Distinguished Research Fellow at TargeGen, a Founder and the Head of Research at Brunswick Biotechnetics, a Research Scientist at General Atomics, and a member of the Member- Macromolecular Chemistry Group at the Boeing Scientific Research Institute and founder of Neuropore. Milan Makale, PhD, Radiation Biology at the University of Alberta.

Milan Makale, PhD

 

Radiation Biology at the University of Alberta. Biomedical engineer, faculty member at UC San Diego Moores Cancer Center.  Specializes in medical devices and imaging, worked in academia and development stage pharmaceutical companies.  A U.S. National Research Council Associate at the U.S. DoD. MS in Biomedical Engineering, at George Washington University, and  worked in functional and structural neuroimaging research at NINDS, NIH Bethesda, MD. Co-founded Engineered Medical Devices Inc., Lemma Pharmaceuticals.  Member of the American Chemical Society, the Society for Neuro-Oncology, and the Whittaker Institute of Bioengineering.

Dr. Ted Dubinsky

 

Dr. Ted Dubinsky serves as the Lawrence A. Mack Endowed Professor of Radiology, Obstetrics and Gynecology, University of Washington School of Medicine and as the Editor in Chief of Ultrasound Quarterly.  Dr. Dubinsky is a well-published and highly recognized luminary in the field of High Intensity Focused Ultrasound, having authored over 100 published peer review papers. At the University of Washington, Dr. Dubinsky served as the Director of Body Imaging an Adjunct Associate Professor of Obstetrics and Gynecology. Dr. Dubinsky achieved his medical degree from the University of Maryland after graduating from Johns Hopkins University.

Dr. Aizik Wolf

 

Dr. Wolf is a world-renowned radiosurgery neurosurgeon who has performed more private practice brain cancer treatments with gamma knife radiosurgery than any other neurosurgeon in the world. A member of numerous professional organizations, including the American Medical Association, American Association of Neurological surgeons, and the International Brain Research Organization, Dr. Wolf is also a founding member of the International Radiosurgery Support Association.

 

Dr. Wolf has been the recipient of numerous grants and research awards.  He has acted as principal investigator for two clinical trials involving treatment for severe head injury, both of which were funded by the National Institutes of Health. Also, the American College of Surgeons presented Dr. Wolf and his investigative team with a Research Award for an abstract detailing a lobectomy procedure. Widely published, Dr. Wolf has authored and co-authored numerous book chapters and journal articles on neurological surgery, including work published in Advances in Neurology and the Journal of Neurosurgery.

 

He has presented his research as an honoured speaker and invited lecturer at many medical meeting and conferences around the world, such as the Annual Meeting of the American Association of Neurological Surgeons, the Society for Neuroscience and the International Stereotactic Radiosurgery Society.

 

Dr. Wolf graduated summa cum laude from Yale Medical School and trained at the University of Minnesota Hospitals. Earlier in his career, Dr. Wolf served as chief of epilepsy and skull-base surgery at the University of Maryland and assistant professor of neurology and neurosurgery. He received his Gamma Knife training at Brown University.

 

Dr. Wolf founded the Miami Neuroscience Center in 1993. Over the past two decades, he and his team have performed nearly 7,000 Gamma Knife surgeries, acquiring a level of expertise unmatched in the field. The team's long-time collaboration also led to a number of medical breakthroughs. The team was the first to make extensive use of radiosurgery to manage multiple metastases. It was also one of the first to apply radiosurgery to treat large-sized benign tumors, and the first nationally to provide Gamma Knife treatments on an outpatient basis.

Professor Dr. László Bognár

 

Professor Bognar graduated from Semmelweis University in 1982 and then obtained a specialist qualification in neurology and neurosurgery in 1986 and 1989, respectively. As of 2005, he has been director of the Clinic of Neurosurgery at the Centre of Medical and Health Sciences of Debrecen University, associate professor, as of 2006, professor. Apart from leading the Clinic, he is an external consultant in child neurosurgery at the Institute.

 

His key area of specialization is the research and treatment of brain tumors. He is greatly experienced in the surgical treatment of cerebrospinal fluid (CSF) circulation disorders, in epileptic surgery and in the operative treatment of cranial deformities. Professor Bognar founded the Rotating Gamma Institute-Debrecen and placed the first Rotating Gamma System (RGS) in Eastern Europe. Professor Bognar lectures around the world on stereotactic radiosurgery.

Dr. Maheep Gaur

 

In 1996 he joined fellowship program in Stereotactic Functional Neurosurgery and Radiosurgery at Stereotaxis and Gamma Knife centre, Fujieda Heisei Memorial Hospital, Shizuoka, Japan, under Dr. Tatsuo Hirai and Dr. Takaaki Takizawa, During this fellowship he participated in about 500 Gamma Knife Surgeries and Micro-recording assisted functional neurosurgery procedures for movement disorders. He learnt various aspects of stereotactic frame based and frameless neuro navigation.

 

On return to India in 1997 he joined Vidyasagar Institute of Mental Health and Neuro Sciences [Vimhans] at New Delhi India as Consultant Neurosurgeon. In 1998 he established first Gamma Knife centre in a dedicated neuroscience centre in SAARC region. He was designated head of Gamma knife Surgery at Vimhans. He has experience of more than 2000 Gamma Knife Treatments collectively. He is the founder of the Asian Radiosurgery Conference and conducted first Asian Gamma Knife Training Program at Saitama Japan.

  • Facebook
  • LinkedIn
  • YouTube

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET MAY DEVELOP FOLLOWING THIS OFFERING.

 

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A REGISTRATION STATEMENT UNDER THE SECURITIES ACT. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBERS IN CONNECTION WITH THIS OFFERING.

 

SUBSCRIBERS WHO ARE NOT “ACCREDITED INVESTORS” (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT) ARE SUBJECT TO LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4. THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES SET FORTH BY EACH SUBSCRIBER IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY SUBSCRIBER IN CONNECTION WITH THIS OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT.

 

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

 

THE COMPANY MAY NOT BE OFFERING THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN WHICH THE SECURITIES ARE NOT BEING OFFERED.

 

THE COMPANY RESERVES THE RIGHT IN ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT OR REJECT IN WHOLE OR IN PART ANY PROSPECTIVE INVESTMENT IN THE SECURITIES OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE AMOUNT OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.

© 2021 by Global Cancer Technology